Secondary Logo

Journal Logo

P-A10 Accumulation and persistence of deleted HIV proviruses following prolonged ART

Anderson, Elizabeth, B.Sci*; Hill, Shawn, MS, MBA*; Bell, Jennifer, RN, BS, CCRC; Simonetti, Francesco, MD*; Rehm, Catherine, BA; Jones, Sara, BS, MBA; Gorelick, Rob, PhD; Kearney, Mary, PhD*

JAIDS Journal of Acquired Immune Deficiency Syndromes: April 2018 - Volume 77 - Issue - p 56
doi: 10.1097/01.qai.0000532505.40030.f8
Abstracts: PDF Only

HIV-1 immunotherapy offers an alternative to cART or as a “functional cure” by eliminating reactivated viral reservoirs. Both cellular and antibody mediated immune responses have been identified which are capable of reducing either HIV-1 infection risk or severity of infection. We present data on both T-cell based (Vacc4x) and antibody based (vacc-C5) vaccine antigen under development for HIV-1 immunotherapy. Vacc4x has undergone phase II trials demonstrating reductions in viral load and sustained anti-HIV-1 T-cell responses. Additional immune modulation, such as that used in cancer immunotherapy, may have utility in HIV-1 Immunotherapy. For this reason we combined Vacc4x with the immune modulator Lenalidomide both in vitro and in a phase I trial of 24 subjects in order to assess the ability of this combination to enhance CD4+ T cell responses. The combination was safe, well tolerated and demonstrated increases in CD4+ T-cell counts after a 2 week vaccine protocol. We have identified that antibodies specific for a heterodimeric peptide construct comprising the C5501-512 and gp41732-744 regions of the HIV envelope protein (Vacc-C5) are correlated with slow disease progression, lower viral load and markers of immune function in HIV-1 patients and are capable of mediating antibody dependent cytotoxicity. We conducted a phase I/II trial of 36 ART treated patients vaccinated with Vacc-C5 antigen. Vacc-C5 was safe, well tolerated and increased anti-Vacc-C5 titre in a subset of patients. These data support the continued development of Vacc4x, Lenalidomide and Vacc-C5 in an HIV-1 immunotherapeutic setting.

*HIV Dynamics and Replication Program, NCI;

Leidos, Biomedical Research Inc; and

Lab of Immunoregulation, NIAID

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.